Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has a beta value of 0.86 and has seen 17.08 million shares traded in the last trading session. The company, currently valued at $2.93B, closed the last trade at $7.49 per share which meant it lost -$0.46 on the day or -5.79% during that session. The RXRX stock price is -110.15% off its 52-week high price of $15.74 and 25.23% above the 52-week low of $5.60. If we look at the company’s 10-day average daily trading volume, we find that it stood at 16.69 million shares traded. The 3-month trading volume is 10.79 million shares.

The consensus among analysts is that Recursion Pharmaceuticals Inc (RXRX) is Buy stock at the moment, with a recommendation rating of 2.43. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.41.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information

Sporting -5.79% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the RXRX stock price touched $7.49 or saw a rise of 13.51%. Year-to-date, Recursion Pharmaceuticals Inc shares have moved 10.80%, while the 5-day performance has seen it change 10.64%. Over the past 30 days, the shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) have changed 13.66%. Short interest in the company has seen 67.1 million shares shorted with days to cover at 4.72.

Wall Street analysts have a consensus price target for the stock at $11, which means that the shares’ value could jump 31.91% from current levels. The projected low price target is $6.0 while the price target rests at a high of $12.0. In that case, then, we find that the current price level is -60.21% off the targeted high while a plunge would see the stock lose 19.89% from current levels.

Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts

Figures show that Recursion Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 0.67% over the past 6 months, with this year growth rate of 0.63%, compared to 16.70% for the industry. Revenue growth from the last financial year stood is estimated to be 50.61%.

7 analysts offering their estimates for the company have set an average revenue estimate of 18.17M for the current quarter. 4 have an estimated revenue figure of 12.97M for the next ending quarter. Year-ago sales stood 10.89M and 13.79M respectively for this quarter and the next, and analysts expect sales will grow by 66.85% for the current quarter and 50.61% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -43.41% over the past 5 years. Earnings growth for 2025 is a modest 2.85% while over the next 5 years, the company’s earnings are expected to increase by 12.00%.

RXRX Dividends

Recursion Pharmaceuticals Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders

Insiders own 3.50% of the company shares, while shares held by institutions stand at 69.04% with a share float percentage of 71.54%. Investors are also buoyed by the number of investors in a company, with Recursion Pharmaceuticals Inc having a total of 355.0 institutions that hold shares in the company. The top two institutional holders are ARK INVESTMENT MANAGEMENT LLC with over 28.14 million shares worth more than $211.07 million. As of 2024-06-30, ARK INVESTMENT MANAGEMENT LLC held 11.924% of shares outstanding.

The other major institutional holder is BAILLIE GIFFORD & CO, with the holding of over 26.59 million shares as of 2024-06-30. The firm’s total holdings are worth over $199.42 million and represent 11.266% of shares outstanding.